JCO Oncology Practice,
Journal Year:
2024,
Volume and Issue:
20(11), P. 1481 - 1490
Published: Nov. 1, 2024
Over
the
next
few
years,
analysis
of
circulating
tumor
DNA
(ctDNA)
through
liquid
biopsy
is
expected
to
enter
clinical
practice
and
revolutionize
approach
biomarker
testing
treatment
selection
in
GI
cancers.
In
fact,
growing
evidence
support
use
ctDNA
as
a
noninvasive,
effective,
highly
specific
tool
for
molecular
profiling
Analysis
blood
has
been
investigated
multiple
settings
including
early
detection,
minimal
residual
disease
evaluation,
diagnosis
evaluation
prognostic/predictive
biomarkers
targeted
selection,
longitudinal
monitoring
response,
identification
resistance
mechanisms.
Here,
we
review
applications,
advantages,
limitations
precision
oncology
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(16), P. 8830 - 8830
Published: Aug. 14, 2024
Tumor
heterogeneity
refers
to
the
diversity
observed
among
tumor
cells:
both
between
different
tumors
(inter-tumor
heterogeneity)
and
within
a
single
(intra-tumor
heterogeneity).
These
cells
can
display
distinct
morphological
phenotypic
characteristics,
including
variations
in
cellular
morphology,
metastatic
potential
variability
treatment
responses
patients.
Therefore,
comprehensive
understanding
of
such
is
necessary
for
deciphering
tumor-specific
mechanisms
that
may
be
diagnostically
therapeutically
valuable.
Innovative
multidisciplinary
approaches
are
needed
understand
this
complex
feature.
In
context,
proteogenomics
has
been
emerging
as
significant
resource
integrating
omics
fields
genomics
proteomics.
By
combining
data
obtained
from
Next-Generation
Sequencing
(NGS)
technologies
mass
spectrometry
(MS)
analyses,
aims
provide
view
heterogeneity.
This
approach
reveals
molecular
alterations
features
related
subtypes,
potentially
identifying
therapeutic
biomarkers.
Many
achievements
have
made;
however,
despite
continuous
advances
proteogenomics-based
methodologies,
several
challenges
remain:
particular
limitations
sensitivity
specificity
lack
optimal
study
models.
review
highlights
impact
on
characterizing
phenotypes,
focusing
critical
current
its
use
clinical
preclinical
models
characterization.
Journal of Biotechnology,
Journal Year:
2023,
Volume and Issue:
380, P. 20 - 28
Published: Dec. 19, 2023
Cancer
stands
as
one
of
the
most
common
and
lethal
diseases,
imposing
a
substantial
burden
on
global
mortality
rates.
Breast
cancer
is
distinct
from
other
forms
in
which
it
primary
cause
death
for
women.
Early
detection
breast
can
significantly
lower
risk
mortality,
improving
prognosis
those
who
are
affected.
The
rate
has
been
steadily
rising,
according
to
epidemiological
data,
especially
since
COVID-19
pandemic.
This
emphasizes
necessity
sensitive
precise
technologies
that
be
utilized
early
diagnosis.
In
this
process,
biomarkers
play
pivotal
role
by
facilitating
diagnosis
cancer.
Currently,
wide
variety
have
identified,
accuracy
These
applied
liquid
biopsies
well
solid
tissues.
context
cancer,
particularly
valuable
determining
predisposed
disease,
predicting
at
time
diagnosis,
selecting
best
course
therapy.
review
comprehensively
explores
recently
developed
gene-based
biofluids
used
conventional
cutting-edge
techniques
employed
Cancers,
Journal Year:
2024,
Volume and Issue:
16(13), P. 2432 - 2432
Published: July 1, 2024
Circulating
tumor
DNA
(ctDNA),
a
fragment
of
found
in
the
bloodstream,
has
emerged
as
revolutionary
tool
cancer
management.
This
review
delves
into
biology
ctDNA,
examining
release
mechanisms,
including
necrosis,
apoptosis,
and
active
secretion,
all
which
offer
information
about
state
nature
tumor.
Comprehensive
profiling
been
enabled
by
methods
such
whole
genome
sequencing
methylation
analysis.
The
low
abundance
ctDNA
fraction
makes
alternative
techniques,
digital
PCR
targeted
next-generation
exome
sequencing,
more
valuable
accurate
for
mutation
detection.
There
are
numerous
clinical
applications
analysis,
non-invasive
liquid
biopsies
minimal
residual
disease
monitoring
to
detect
recurrence,
personalized
medicine
therapy
identification,
early
detection,
real-time
evaluation
therapeutic
response.
Integrating
analysis
routine
practice
creates
promising
avenues
successful
care,
from
diagnosis
treatment
follow-up.
JCO Oncology Practice,
Journal Year:
2024,
Volume and Issue:
20(11), P. 1481 - 1490
Published: Nov. 1, 2024
Over
the
next
few
years,
analysis
of
circulating
tumor
DNA
(ctDNA)
through
liquid
biopsy
is
expected
to
enter
clinical
practice
and
revolutionize
approach
biomarker
testing
treatment
selection
in
GI
cancers.
In
fact,
growing
evidence
support
use
ctDNA
as
a
noninvasive,
effective,
highly
specific
tool
for
molecular
profiling
Analysis
blood
has
been
investigated
multiple
settings
including
early
detection,
minimal
residual
disease
evaluation,
diagnosis
evaluation
prognostic/predictive
biomarkers
targeted
selection,
longitudinal
monitoring
response,
identification
resistance
mechanisms.
Here,
we
review
applications,
advantages,
limitations
precision
oncology
